Assembly Biosciences (ASMB)
Develops antiviral and liver-disease candidates through discovery and clinical development.
$25.70
vs last close+0.26 (+1.03%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
estimated · in 48 days
EPS estimate
−$0.66
Revenue estimate
$9.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.57−$1.17−$1.33−$0.72$2.48−$0.54−$0.20Pending
Estimate−$1.75−$2.01−$0.65−$0.50−$0.51−$0.73−$0.72−$0.66
Surprise+10.3%+41.8%−103.6%−44.0%+586.3%+26.0%+72.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$7.4M$9.4M$9.6M$10.8M$42.5M$8.2M$13.4MPending
Estimate$3.6M$7.4M$9.3M$7.5M$7.4M$9.3M$8.6M$9.1M
Surprise+107.2%+27.0%+3.2%+44.6%+472.2%−11.4%+55.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.22 | — | — |
| Sep 2027 | −$1.04 | — | — |
| Jun 2027 | −$1.04 | — | — |
| Mar 2027 | −$0.61 | — | — |
| Dec 2026 | $0.48 | — | — |
| Nov 2026 | −$0.66 | — | — |
| Aug 2026 | −$0.72 | −$0.20 | +72.4% |
| May 2026 | −$0.73 | −$0.54 | +26.0% |
| Mar 2026 | −$0.51 | $2.48 | +586.3% |
| Nov 2025 | −$0.50 | −$0.72 | −44.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.22 | — | — | $30.5M | — | — | — |
| Sep 2027 | −$1.04 | — | — | $2.0M | — | — | — |
| Jun 2027 | −$1.04 | — | — | $2.0M | — | — | — |
| Mar 2027 | −$0.61 | — | — | $10.6M | — | — | — |
| Dec 2026 | $0.48 | — | — | $43.1M | — | — | — |
| Nov 9, 2026 | −$0.66 | — | — | $9.1M | — | — | — |
| Aug 13, 2026 | −$0.72 | −$0.20 | +72.4% | $8.6M | $13.4M | +55.5% | +10.0% |
| May 7, 2026 | −$0.73 | −$0.54 | +26.0% | $9.3M | $8.2M | −11.4% | −3.9% |
| Mar 19, 2026 | −$0.51 | $2.48 | +586.3% | $7.4M | $42.5M | +472.2% | +3.5% |
| Nov 10, 2025 | −$0.50 | −$0.72 | −44.0% | $7.5M | $10.8M | +44.6% | +2.8% |
| Aug 6, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 27, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 22, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 4, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 7, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 2, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Mar 11, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 13, 2015 |